Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | CASR | P41180 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816769 | 1.00 | ADRB3 (0.66) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| SCHEMBL4816774 | 1.00 | ADRB3 (0.66) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| SCHEMBL13959117 | 0.86 | ADRB3 (0.70) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| SCHEMBL10594616 | 0.81 | ADRB3 (0.80) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| SCHEMBL11242745 | 0.81 | ADRB2 (0.73) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| Hydrochloric Acid SCHEMBL11248041 | 0.80 | ADRB2 (0.73) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| Cgp-12177 SCHEMBL2016211 | 0.80 | ADRB2 (1.00) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| Cgp-12177 SCHEMBL12329633 | 0.80 | ADRB2 (1.00) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| SCHEMBL13889875 | 0.79 | ADRB3 (0.70) | ADRB3ADRB2ADRB1ALOX15CYP1A2 | |
| Cgp-12177 SCHEMBL4538049 | 0.79 | ADRB2 (1.00) | ADRB3ADRB2ADRB1ALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679304-A1 | AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-6649603-B2 | For therapy of metabolic disorders related to insulin resistance or hyperglycemia | WYETH | 2003-11-18 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1328512-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | WYETH (US) | 2003-02-06 | — | — | US | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6498170-B2 | 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
| WO-2002006221-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885ADRB1 1/4885 |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB2 3/4885ADRB1 2/4885 |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB2 3/4885ADRB1 2/4885 |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB2 3/4885ADRB1 2/4885 |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | ADRB3 5/4885ADRB2 1/4885ADRB1 4/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885ADRB2 3/4885ADRB1 1/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB2 3/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.